Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co Ltd is a Chinese pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the domestic market.
Business. Shenyang Xingqi Pharmaceutical Co Ltd (300573.SZ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Shenyang and operates within the broader healthcare sector. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shenyang Xingqi Pharmaceutical Co Ltd (300573.SZ) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Shenyang and operates within the broader healthcare sector. It is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Shenyang Xingqi Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 1.86, indicating the company can cover its short-term liabilities with its short-term assets. The company's debt-to-equity ratio is 0.05, suggesting a conservative capital structure with minimal reliance on debt financing. However, the company has a negative net cash position after subtracting total debt, which raises some liquidity concerns.
In terms of profitability, the company's return on equity (ROE) is 35.18%, and its return on assets (ROA) is 27.41%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures are well above the typical thresholds for the pharmaceutical industry, suggesting that the company is performing better than the median in its sector.
The company's revenue is primarily concentrated in its domestic operations, with no significant international revenue disclosed in the available data. This concentration may expose the company to regional economic and regulatory risks, particularly in the Chinese market.
Looking at the company's growth trajectory, the available data does not provide specific forward-looking revenue projections. However, the company's operating cash flow of 753,388,790 CNY and free cash flow of 186,003,720 CNY suggest a healthy cash-generating business. The capital expenditure of -270,526,700 CNY indicates that the company is not currently investing heavily in new projects or infrastructure.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The risk assessment highlights the negative net cash position as a key flag, which could impact the company's ability to meet short-term obligations. The company has not disclosed any significant dilution sources in the available documents, and there is no indication of near-term pressure for equity issuance.
Recent events and filings do not show any major corporate actions or significant changes in the company's operations or strategy. The company's ESG scores indicate a strong governance profile with a score of 86.47 and a moderate social pillar score of 52.11, with no ESG controversies reported.
- The company has a strong ROE and ROA, indicating efficient use of equity and assets to generate profit.
- The company maintains a conservative capital structure with a low debt-to-equity ratio.
- The company's liquidity position is strong, but the negative net cash position after subtracting total debt raises some concerns.
- The company's revenue is primarily concentrated in the domestic market, which may expose it to regional risks.
- The company has a low dilution risk and no significant dilution sources disclosed.
- The company's ESG profile is strong, particularly in governance, with no ESG controversies reported.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Shenyang Xingqi Pharmaceutical Co Ltd Market data — financials · 2026-05-26
- Shenyang Xingqi Pharmaceutical Co Ltd Market data — ESG · 2026-05-26